Sole bookrunner Canaccord Genuity and lead manager Laidlaw will assist
By Devika Patel
Knoxville, Tenn., July 10 – Actinium Pharmaceuticals, Inc. said the underwriters for its public offering of stock opted to exercise the deal’s $1.18 million greenshoe in part for total proceeds of $13.7 million. The deal was announced June 24 and priced for $12.53 million with the greenshoe on June 30.
The company sold 1,827,123 common shares at $7.50 per share. The price per share is a 14.29% discount to the June 24 closing share price of $8.75. Of the shares, 157,123 were part of the partially exercised greenshoe.
Canaccord Genuity Inc. was the sole bookrunner.
Proceeds will be used for general corporate purposes, including capital expenditures, the advancement of drug candidates in clinical trials, preclinical trials and working capital needs.
The biopharmaceutical company is based in New York.
| Issuer: | Actinium Pharmaceuticals, Inc.
|
| Issue: | Common stock
|
| Amount: | $13,703,423 (including $1,178,423 greenshoe)
|
| Shares: | 1,827,123
|
| Price: | $7.50
|
| Warrants: | No
|
| Bookrunner: | Canaccord Genuity Inc.
|
| Lead manager: | Laidlaw & Co. (UK) Ltd.
|
| Co-manager: | MLV & Co.
|
| Announcement date: | June 24
|
| Pricing date: | June 25
|
| Settlement date: | July 10
|
| Stock symbol: | NYSE: ATNM
|
| Stock price: | $8.75 at close June 24
|
| Market capitalization: | $186.6 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
